Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Article processing charge (APC)
Books and Events
Books
Events
COVID-19: a short message to rheumatologists
1
Department of Rheumatology and Rehabilitation, Poznań University of Medical Sciences, Poland
2
Department of Rheumatology and Osteoporosis, Józef Struś Memorial Multidisciplinary Municipal Hospital
in Poznań, Poland
Online publication date: 2021-09-08
Reumatologia 2021;(Konferencja Pacjent post-COVID-owy. Co zostaje, a co się zmienia? 1):130-133
ABSTRACT
For several months, SARS-CoV-2 virus infection, which sometimes causes critical COVID-19 disease primarily with lung involvement, has been the one and only medical and scientific topic. The widespread occurrence of this type of coronavirus has led to a global pandemic and a huge social confusion that has had and will have a significant impact on our lives.
From the point of view of a specialist in rheumatology and internal medicine, currently performing duties of a medical doctor of infectious diseases in the department of rheumatology in a temporarily uniform hospital in Poznań, Poland, various questions and reflections arise.
From the point of view of a specialist in rheumatology and internal medicine, currently performing duties of a medical doctor of infectious diseases in the department of rheumatology in a temporarily uniform hospital in Poznań, Poland, various questions and reflections arise.
REFERENCES (13)
1.
Savarino A, Boelaert JR, Cassone A, et. al. Effects of Chloroquine on Viral Infections: An Old Drug Against Today’s Diseases? Lancet Infect Dis 2002, 3: 722-727, DOI: 10.1016/s1473-3099(03)00806-5.
2.
Wolfram J, Nizzero S, Liu H, et al. A Chloroquine-Induced Macrophage-Preconditioning Strategy for Improved Nanodelivery. Sci Rep 2017, 7: 13738, DOI: 10.1038/s41598-017-14221-2.
3.
Hu YT, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol 2020: 1-3, DOI: 10.1038/s41565-020-0674-9 [Epub ahead of print].
4.
Mehra MR, Desai SS, Ruschitzka F, Patel AN. Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis. 2020, https://doi.org/10.1016/ S0140-6736(20)31180-6.
5.
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet 2020; 395: e30-e31, DOI: 10.1016/S0140-6736(20)30304-4.
6.
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020 (in press), DOI: 10.1016/j.cell.2020.02.052.
7.
Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. ChinaXiv 2020, 202003.00026.
8.
SIMIT – Societa` Italiana di Malattie Infettive e Tropicali – Sezione Regione Lombardia. Vademecum per la cura delle persone con malattia da COVI-19. Edizione 2.0, 13 marzo 2020. http://www.simit.org/medias/15...- vademecum-13-03-202.pdf.
9.
Sönmez HE, Demir S, Bilginer Y, Özen S. Anakinra treatment in macrophage activation syndrome: a single center experience and systemic review of literature. Clin Rheumatol 2018; 37: 3329-3335, DOI: 10.1007/s10067-018-4095-1.
10.
Ferro F, Elefante E, Baldini C, et al. COVID-19: the new challenge for rheumatologists. Clin Exp Rheumatol 2020; 38: 175-180.
11.
Monti S, Balduzzi S, Delvino P, et al. Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies. Ann Rheum Dis 2020; pii: annrheumdis-2020-217424, DOI: 10.1136/annrheumdis-2020-217424 [Epub ahead of print].
12.
Covid-19 in Immune-Mediated Inflammatory Diseases – Case Series from New York. Downloaded from nejm.org on May 10, 2020, DOI: 10.1056/NEJMc2009567.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
